Source disclosure: February 26, 2026, 15:30 JST
Nissan Chemical Corporation [4021.T]
TOKYO, Feb 26 (Pulse News Wire) -- Nissan Chemical Corporation (4021.T), led by Representative Director President Yoshiyuki Hagiwara, announced significant changes in its executive appointments effective April 1, 2026. The company detailed several key personnel moves across various departments and subsidiaries.
Among the notable promotions is that of Hiroyuki Omon, who will continue as Executive Vice President and Chief Technology Officer (CTO). Additionally, Ken Matsuo will be promoted to Executive Vice President and CRO (Chief Risk Officer), taking on new responsibilities including leading the newly established Risk Management Department. This department consolidates functions previously handled by the Corporate Planning Division's Risk Compliance Room and Environmental Safety & Quality Assurance Department. Meanwhile, Toshio Nishimura will retain his position as an Executive Vice President but will shift focus to lead the newly formed Health Care Business Unit while continuing his role as CEO of Japan Polytec Corporation.
The company also highlighted changes in leadership roles within its subsidiaries. For instance, Yusuke Sato will remain as an Executive Vice President and Chairman of Nissan Chemical Europe SAS, Nissan Chemical Shanghai Co., Ltd., Nissan Bharat Rasayan Pvt. Ltd., and Nissan Chemical Agro Korea Ltd. Additionally, Kiyoharu Ishikawa will take over as the Chairman of Nissan Chemical Agro Singapore Pte. Ltd. Other executives such as Shun'ichi Kimura, Masayuki Satou, and Hiroshi Arashi were appointed to various positions including Research Institute Directors and Deputy General Managers.
Furthermore, the company outlined plans for upcoming formal decisions at its 156th Annual General Meeting scheduled for June 25, 2026. These include the appointment of Yasuhiko Nakaya as Senior Advisor and the retirement of Kaneyuki Katayama as an auditor. The meeting will also see the reappointment of Wakami Oie as an auditor and Wataru Kawashima as both an auditor and head of the Human Resources DepartmentHealth Promotion Office.
In addition to these executive changes, Nissan Chemical Corporation made several other major personnel adjustments affecting various business units and research institutions. Notable among these is the consolidation of the Pharmaceutical Research Department and Medical Device Research Department under the Material Science Research Institute, where a new Healthcare Research Department has been established. Key individuals like Junji Saeki and Kiyoshi Iwanabe have taken up new roles reflecting this organizational realignment.
AI-translated content. 🟡 Confidence: Standard See terms • Original filing